Jiangsu Hengrui Medicine Co., Ltd. (SHA: 600276)
44.40
-0.60 (-1.33%)
Sep 6, 2024, 3:00 PM CST
Jiangsu Hengrui Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Net Income | 5,426 | 4,302 | 3,906 | 4,530 | 6,328 | 5,328 | Upgrade
|
Depreciation & Amortization | 759.22 | 692.57 | 577.89 | 520.41 | 448.39 | 618.52 | Upgrade
|
Other Amortization | 110.51 | 101.37 | 66.26 | 20.33 | 27.27 | 27.32 | Upgrade
|
Loss (Gain) From Sale of Assets | -2.57 | -3.16 | -5.47 | -3.37 | -2.98 | 0.43 | Upgrade
|
Asset Writedown & Restructuring Costs | 76.25 | 76.21 | 131.24 | -117.52 | -19.02 | - | Upgrade
|
Loss (Gain) From Sale of Investments | 35.05 | 35.62 | -533.84 | -169.57 | -339.96 | -346.8 | Upgrade
|
Provision & Write-off of Bad Debts | 33.9 | -15.77 | 26.02 | -3.87 | 9.36 | 17.65 | Upgrade
|
Other Operating Activities | -0.54 | 17.02 | -67.79 | -27.8 | -14.88 | -0.52 | Upgrade
|
Change in Accounts Receivable | -651.61 | 2,036 | -2,285 | -868.27 | -3,486 | -2,892 | Upgrade
|
Change in Inventory | 159.7 | 129.11 | -52.68 | -631.22 | -173.62 | -581.7 | Upgrade
|
Change in Accounts Payable | 1,961 | 315.32 | -511.05 | 809.7 | 222.12 | 1,417 | Upgrade
|
Change in Other Net Operating Assets | 75.28 | 55.47 | 34.98 | 253.16 | 414.48 | 182.33 | Upgrade
|
Operating Cash Flow | 7,801 | 7,644 | 1,265 | 4,219 | 3,432 | 3,817 | Upgrade
|
Operating Cash Flow Growth | 136.74% | 504.12% | -70.01% | 22.93% | -10.08% | 37.58% | Upgrade
|
Capital Expenditures | -1,463 | -1,484 | -1,992 | -1,665 | -554.33 | -561.35 | Upgrade
|
Sale of Property, Plant & Equipment | 21.68 | 20.18 | 20.21 | 16.11 | 3.56 | 1.2 | Upgrade
|
Divestitures | - | - | 36.05 | - | - | - | Upgrade
|
Investment in Securities | 81.68 | 2,590 | 2,160 | 842.49 | 2,007 | -1,693 | Upgrade
|
Other Investing Activities | 60.34 | 95.51 | 166.49 | 259.77 | 341.42 | 307.36 | Upgrade
|
Investing Cash Flow | -1,299 | 1,222 | 390.29 | -546.26 | 1,798 | -1,945 | Upgrade
|
Short-Term Debt Issued | - | 21.1 | 1,260 | - | - | - | Upgrade
|
Total Debt Issued | 811.01 | 21.1 | 1,260 | - | - | - | Upgrade
|
Short-Term Debt Repaid | - | -1,281 | - | - | - | - | Upgrade
|
Long-Term Debt Repaid | - | -34.33 | -36.28 | -31.05 | - | - | Upgrade
|
Total Debt Repaid | -864.03 | -1,315 | -36.28 | -31.05 | - | - | Upgrade
|
Net Debt Issued (Repaid) | -53.02 | -1,294 | 1,224 | -31.05 | - | - | Upgrade
|
Issuance of Common Stock | - | - | - | - | 1,171 | - | Upgrade
|
Repurchase of Common Stock | -567.79 | -827.26 | -1,066 | -235.16 | -11.98 | -4.63 | Upgrade
|
Common Dividends Paid | -39.34 | -1,023 | -1,016 | -1,066 | -1,017 | -810.89 | Upgrade
|
Other Financing Activities | -1.02 | - | 538.86 | 334.14 | 149.1 | 97.01 | Upgrade
|
Financing Cash Flow | -661.18 | -3,144 | -318.77 | -998.32 | 291.19 | -718.51 | Upgrade
|
Foreign Exchange Rate Adjustments | -21.01 | 12.53 | 80.5 | -16.87 | -89.08 | 12.31 | Upgrade
|
Net Cash Flow | 5,819 | 5,734 | 1,417 | 2,657 | 5,432 | 1,165 | Upgrade
|
Free Cash Flow | 6,338 | 6,160 | -726.91 | 2,554 | 2,878 | 3,255 | Upgrade
|
Free Cash Flow Growth | 252.71% | - | - | -11.24% | -11.61% | 45.00% | Upgrade
|
Free Cash Flow Margin | 25.10% | 26.99% | -3.42% | 9.86% | 10.38% | 13.98% | Upgrade
|
Free Cash Flow Per Share | 1.01 | 0.97 | -0.11 | 0.40 | 0.45 | 0.51 | Upgrade
|
Cash Interest Paid | 1.02 | - | - | - | - | - | Upgrade
|
Cash Income Tax Paid | 1,931 | 1,568 | 1,631 | 1,607 | 3,022 | 2,428 | Upgrade
|
Levered Free Cash Flow | 6,865 | 4,879 | -2,030 | 1,151 | 2,583 | 9,118 | Upgrade
|
Unlevered Free Cash Flow | 6,869 | 4,883 | -2,026 | 1,154 | 2,583 | 9,118 | Upgrade
|
Change in Net Working Capital | -3,962 | -2,796 | 2,620 | 219.28 | 1,571 | -5,411 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.